Cancer-associated myositis before and after the COVID-19 pandemic onset: a changing trend
During the COVID-19 pandemic, there was a significant impact on the management of non-COVID-19 related diseases, potentially increasing the incidence of paraneoplastic syndromes such as cancer-associated myositis (CAM).The aim of this study is to determine the incidence of CAM in our cohort before a...
Gespeichert in:
| Veröffentlicht in: | Clinical and experimental rheumatology 2024-02, Vol.42 (2), p.316-320 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 320 |
|---|---|
| container_issue | 2 |
| container_start_page | 316 |
| container_title | Clinical and experimental rheumatology |
| container_volume | 42 |
| creator | Costa, Filipa M Campanilho-Marques, Raquel Dourado, Eduardo Bandeira, Matilde Correia, Bianca Melo, Ana Teresa Saraiva, Fernando Barreira, Sofia C Fonseca, João Eurico |
| description | During the COVID-19 pandemic, there was a significant impact on the management of non-COVID-19 related diseases, potentially increasing the incidence of paraneoplastic syndromes such as cancer-associated myositis (CAM).The aim of this study is to determine the incidence of CAM in our cohort before and after the COVID-19 pandemic onset.
We included patients with idiopathic inflammatory myopathy (IIM), diagnosed between June 2016 and June 2023. The patients were divided into two groups according to the date of IIM diagnosis.
We included 132 patients; 65.1% (n=86) were diagnosed prior to and 34.9% (n=46) after the COVID-19 pandemic. The most common IIM was dermatomyositis (DM) before and after the COVID-19 pandemic onset (p=0.750). The most frequent myositis-specific antibody (MSA) before the COVID-19 pandemic was anti-Mi2 (15.1%). After the COVID-19 pandemic onset, anti-TIF1γ was the most common MSA (21.7%), with a significantly higher relative prevalence (p=0.006). The incidence of CAM was significantly higher after the COVID-19 pandemic onset (11 vs. 3 new cases, p |
| doi_str_mv | 10.55563/clinexprheumatol/jv9ey8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2958295120</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2958295120</sourcerecordid><originalsourceid>FETCH-LOGICAL-c310t-b36663119f13e6a46804d7692eaa7f5a3af3172c5b1b142901998db961a348563</originalsourceid><addsrcrecordid>eNpdkMlOwzAQhi0EoqXwCshHLqF2HDs2N1S2Ski9ACqnaOJM2lRZiu0g-vZEtHDgMBpp9C-ajxDK2bWUUomprasWv7ZujX0Doaunm0-DO31ExlwaETGjl8dkzISJIy3VckTOvN8wFiup0lMyEjrRmpl0TN5n0Fp0EXjf2QoCFrTZdb4Klac5lp1DCm1BoQzoaFgjnS3e5ncRN3Q73LGpLO1aj-GGArVraFdVu6LBYVuck5MSao8Xhz0hrw_3L7On6HnxOJ_dPkdWcBaiXCilBOem5AIVJEqzpEiViREgLSUIKAVPYytznvMkNowbo4vcKA4iGX4TE3K1z9267qNHH7Km8hbrGlrsep_FRupheMwGqd5Lreu8d1hmW1c14HYZZ9kP2Ow_2GwPdrBeHlr6vMHiz_hLUnwD9Xd6sg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2958295120</pqid></control><display><type>article</type><title>Cancer-associated myositis before and after the COVID-19 pandemic onset: a changing trend</title><source>Alma/SFX Local Collection</source><creator>Costa, Filipa M ; Campanilho-Marques, Raquel ; Dourado, Eduardo ; Bandeira, Matilde ; Correia, Bianca ; Melo, Ana Teresa ; Saraiva, Fernando ; Barreira, Sofia C ; Fonseca, João Eurico</creator><creatorcontrib>Costa, Filipa M ; Campanilho-Marques, Raquel ; Dourado, Eduardo ; Bandeira, Matilde ; Correia, Bianca ; Melo, Ana Teresa ; Saraiva, Fernando ; Barreira, Sofia C ; Fonseca, João Eurico</creatorcontrib><description>During the COVID-19 pandemic, there was a significant impact on the management of non-COVID-19 related diseases, potentially increasing the incidence of paraneoplastic syndromes such as cancer-associated myositis (CAM).The aim of this study is to determine the incidence of CAM in our cohort before and after the COVID-19 pandemic onset.
We included patients with idiopathic inflammatory myopathy (IIM), diagnosed between June 2016 and June 2023. The patients were divided into two groups according to the date of IIM diagnosis.
We included 132 patients; 65.1% (n=86) were diagnosed prior to and 34.9% (n=46) after the COVID-19 pandemic. The most common IIM was dermatomyositis (DM) before and after the COVID-19 pandemic onset (p=0.750). The most frequent myositis-specific antibody (MSA) before the COVID-19 pandemic was anti-Mi2 (15.1%). After the COVID-19 pandemic onset, anti-TIF1γ was the most common MSA (21.7%), with a significantly higher relative prevalence (p=0.006). The incidence of CAM was significantly higher after the COVID-19 pandemic onset (11 vs. 3 new cases, p<0.002). Patients with CAM more frequently had anti-TIF1γ-positivity (p<0.001) and a diagnosis after the pandemic (p=0.001) than non-CAM-IIM patients. No significant differences were found regarding vaccination status or previous COVID-19 infection in CAM and non-CAM-IIM patients. Diagnosis after the COVID-19 pandemic was an independent predictor of CAM among IIM patients (OR 0.012, 95% CI 0.000-0.400, p=0.013), regardless of age, sex or previous COVID-19 infection.
There was a significant increase in the incidence of CAM after the COVID-19 pandemic. IIM diagnosis after the COVID-19 pandemic was an independent predictor of CAM.</description><identifier>ISSN: 0392-856X</identifier><identifier>ISSN: 1593-098X</identifier><identifier>EISSN: 1593-098X</identifier><identifier>DOI: 10.55563/clinexprheumatol/jv9ey8</identifier><identifier>PMID: 38488097</identifier><language>eng</language><publisher>Italy</publisher><ispartof>Clinical and experimental rheumatology, 2024-02, Vol.42 (2), p.316-320</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38488097$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Costa, Filipa M</creatorcontrib><creatorcontrib>Campanilho-Marques, Raquel</creatorcontrib><creatorcontrib>Dourado, Eduardo</creatorcontrib><creatorcontrib>Bandeira, Matilde</creatorcontrib><creatorcontrib>Correia, Bianca</creatorcontrib><creatorcontrib>Melo, Ana Teresa</creatorcontrib><creatorcontrib>Saraiva, Fernando</creatorcontrib><creatorcontrib>Barreira, Sofia C</creatorcontrib><creatorcontrib>Fonseca, João Eurico</creatorcontrib><title>Cancer-associated myositis before and after the COVID-19 pandemic onset: a changing trend</title><title>Clinical and experimental rheumatology</title><addtitle>Clin Exp Rheumatol</addtitle><description>During the COVID-19 pandemic, there was a significant impact on the management of non-COVID-19 related diseases, potentially increasing the incidence of paraneoplastic syndromes such as cancer-associated myositis (CAM).The aim of this study is to determine the incidence of CAM in our cohort before and after the COVID-19 pandemic onset.
We included patients with idiopathic inflammatory myopathy (IIM), diagnosed between June 2016 and June 2023. The patients were divided into two groups according to the date of IIM diagnosis.
We included 132 patients; 65.1% (n=86) were diagnosed prior to and 34.9% (n=46) after the COVID-19 pandemic. The most common IIM was dermatomyositis (DM) before and after the COVID-19 pandemic onset (p=0.750). The most frequent myositis-specific antibody (MSA) before the COVID-19 pandemic was anti-Mi2 (15.1%). After the COVID-19 pandemic onset, anti-TIF1γ was the most common MSA (21.7%), with a significantly higher relative prevalence (p=0.006). The incidence of CAM was significantly higher after the COVID-19 pandemic onset (11 vs. 3 new cases, p<0.002). Patients with CAM more frequently had anti-TIF1γ-positivity (p<0.001) and a diagnosis after the pandemic (p=0.001) than non-CAM-IIM patients. No significant differences were found regarding vaccination status or previous COVID-19 infection in CAM and non-CAM-IIM patients. Diagnosis after the COVID-19 pandemic was an independent predictor of CAM among IIM patients (OR 0.012, 95% CI 0.000-0.400, p=0.013), regardless of age, sex or previous COVID-19 infection.
There was a significant increase in the incidence of CAM after the COVID-19 pandemic. IIM diagnosis after the COVID-19 pandemic was an independent predictor of CAM.</description><issn>0392-856X</issn><issn>1593-098X</issn><issn>1593-098X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdkMlOwzAQhi0EoqXwCshHLqF2HDs2N1S2Ski9ACqnaOJM2lRZiu0g-vZEtHDgMBpp9C-ajxDK2bWUUomprasWv7ZujX0Doaunm0-DO31ExlwaETGjl8dkzISJIy3VckTOvN8wFiup0lMyEjrRmpl0TN5n0Fp0EXjf2QoCFrTZdb4Klac5lp1DCm1BoQzoaFgjnS3e5ncRN3Q73LGpLO1aj-GGArVraFdVu6LBYVuck5MSao8Xhz0hrw_3L7On6HnxOJ_dPkdWcBaiXCilBOem5AIVJEqzpEiViREgLSUIKAVPYytznvMkNowbo4vcKA4iGX4TE3K1z9267qNHH7Km8hbrGlrsep_FRupheMwGqd5Lreu8d1hmW1c14HYZZ9kP2Ow_2GwPdrBeHlr6vMHiz_hLUnwD9Xd6sg</recordid><startdate>20240201</startdate><enddate>20240201</enddate><creator>Costa, Filipa M</creator><creator>Campanilho-Marques, Raquel</creator><creator>Dourado, Eduardo</creator><creator>Bandeira, Matilde</creator><creator>Correia, Bianca</creator><creator>Melo, Ana Teresa</creator><creator>Saraiva, Fernando</creator><creator>Barreira, Sofia C</creator><creator>Fonseca, João Eurico</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240201</creationdate><title>Cancer-associated myositis before and after the COVID-19 pandemic onset: a changing trend</title><author>Costa, Filipa M ; Campanilho-Marques, Raquel ; Dourado, Eduardo ; Bandeira, Matilde ; Correia, Bianca ; Melo, Ana Teresa ; Saraiva, Fernando ; Barreira, Sofia C ; Fonseca, João Eurico</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c310t-b36663119f13e6a46804d7692eaa7f5a3af3172c5b1b142901998db961a348563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Costa, Filipa M</creatorcontrib><creatorcontrib>Campanilho-Marques, Raquel</creatorcontrib><creatorcontrib>Dourado, Eduardo</creatorcontrib><creatorcontrib>Bandeira, Matilde</creatorcontrib><creatorcontrib>Correia, Bianca</creatorcontrib><creatorcontrib>Melo, Ana Teresa</creatorcontrib><creatorcontrib>Saraiva, Fernando</creatorcontrib><creatorcontrib>Barreira, Sofia C</creatorcontrib><creatorcontrib>Fonseca, João Eurico</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Costa, Filipa M</au><au>Campanilho-Marques, Raquel</au><au>Dourado, Eduardo</au><au>Bandeira, Matilde</au><au>Correia, Bianca</au><au>Melo, Ana Teresa</au><au>Saraiva, Fernando</au><au>Barreira, Sofia C</au><au>Fonseca, João Eurico</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer-associated myositis before and after the COVID-19 pandemic onset: a changing trend</atitle><jtitle>Clinical and experimental rheumatology</jtitle><addtitle>Clin Exp Rheumatol</addtitle><date>2024-02-01</date><risdate>2024</risdate><volume>42</volume><issue>2</issue><spage>316</spage><epage>320</epage><pages>316-320</pages><issn>0392-856X</issn><issn>1593-098X</issn><eissn>1593-098X</eissn><abstract>During the COVID-19 pandemic, there was a significant impact on the management of non-COVID-19 related diseases, potentially increasing the incidence of paraneoplastic syndromes such as cancer-associated myositis (CAM).The aim of this study is to determine the incidence of CAM in our cohort before and after the COVID-19 pandemic onset.
We included patients with idiopathic inflammatory myopathy (IIM), diagnosed between June 2016 and June 2023. The patients were divided into two groups according to the date of IIM diagnosis.
We included 132 patients; 65.1% (n=86) were diagnosed prior to and 34.9% (n=46) after the COVID-19 pandemic. The most common IIM was dermatomyositis (DM) before and after the COVID-19 pandemic onset (p=0.750). The most frequent myositis-specific antibody (MSA) before the COVID-19 pandemic was anti-Mi2 (15.1%). After the COVID-19 pandemic onset, anti-TIF1γ was the most common MSA (21.7%), with a significantly higher relative prevalence (p=0.006). The incidence of CAM was significantly higher after the COVID-19 pandemic onset (11 vs. 3 new cases, p<0.002). Patients with CAM more frequently had anti-TIF1γ-positivity (p<0.001) and a diagnosis after the pandemic (p=0.001) than non-CAM-IIM patients. No significant differences were found regarding vaccination status or previous COVID-19 infection in CAM and non-CAM-IIM patients. Diagnosis after the COVID-19 pandemic was an independent predictor of CAM among IIM patients (OR 0.012, 95% CI 0.000-0.400, p=0.013), regardless of age, sex or previous COVID-19 infection.
There was a significant increase in the incidence of CAM after the COVID-19 pandemic. IIM diagnosis after the COVID-19 pandemic was an independent predictor of CAM.</abstract><cop>Italy</cop><pmid>38488097</pmid><doi>10.55563/clinexprheumatol/jv9ey8</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0392-856X |
| ispartof | Clinical and experimental rheumatology, 2024-02, Vol.42 (2), p.316-320 |
| issn | 0392-856X 1593-098X 1593-098X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2958295120 |
| source | Alma/SFX Local Collection |
| title | Cancer-associated myositis before and after the COVID-19 pandemic onset: a changing trend |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T13%3A41%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer-associated%20myositis%20before%20and%20after%20the%20COVID-19%20pandemic%20onset:%20a%20changing%20trend&rft.jtitle=Clinical%20and%20experimental%20rheumatology&rft.au=Costa,%20Filipa%20M&rft.date=2024-02-01&rft.volume=42&rft.issue=2&rft.spage=316&rft.epage=320&rft.pages=316-320&rft.issn=0392-856X&rft.eissn=1593-098X&rft_id=info:doi/10.55563/clinexprheumatol/jv9ey8&rft_dat=%3Cproquest_cross%3E2958295120%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2958295120&rft_id=info:pmid/38488097&rfr_iscdi=true |